Lerink Swann analyst Geoff Porges weighed in today with a few insights on Celgene Corporation (NASDAQ:CELG), following investor meeting with Celgene’s CFO Peter Kellogg and Investor Relations …
Valeant: Sidelined on Uncertainty, but Short-Term Set-Up is a Positive Earlier this month, the rumor mill was clattering that Valeant Pharmaceuticals Intl Inc …
Celgene Corporation (NASDAQ:CELG) announced findings from the ACTIVE phase 3b clinical trial of OTEZLA® (apremilast), the Company’s oral, selective inhibitor of phosphodiesterase 4 …
In a research report released Friday, BTIG analyst Dane Leone reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price target …
Yesterday, Celgene Corporation (NASDAQ:CELG) shares were trading up 6% after posting a robust third-quarter EPS beat. Subsequently, Cantor analyst Mara Goldstein reiterates a …
In a research report published Thursday, Canaccord analyst John Newman reiterated a Buy rating on shares of Celgene Corporation (NASDAQ:CELG) with a price target …
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,969 million for the third quarter of 2016, a 28 percent increase from the same period …
Celgene Corporation (NASDAQ:CELG) announced that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral OTEZLA®(apremilast) following …
In Vienna, Austria at the United European Gastroenterology Week (UEGW) Conference held from October 15th through the 19th, Celgene Corporation (NASDAQ:CELG) announced new …
Celgene Corporation (NASDAQ:CELG) and Sage Bionetworks announced a collaboration to develop an iPhone application utilizing the Apple ResearchKit framework to improve the understanding of …
